ABL is a pure play CDMO specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies, and other immunotherapies. ABL’s mission is to provide GMP viral vectors from early stage to market, contributing to the success of its clients’ immunotherapy innovations. ABL’s CDMO services include bulk drug substance, fill/finish of drug products, process and assay development as well as bioanalytical testing. ABL is a subsidiary of Institut Mérieux and operates from various locations in Europe and the US. For more information: www.abl-biomanufacturing.com